These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease. Fasching P Diabetologia; 1998 Jun; 41(6):743-4. PubMed ID: 9662063 [No Abstract] [Full Text] [Related]
12. Summaries for patients. How do older diabetes drugs compare in their effects on heart and blood vessel disease? Ann Intern Med; 2012 Nov; 157(9):I-28. PubMed ID: 23128878 [No Abstract] [Full Text] [Related]
13. Don't throw the baby out with the bath water: mortality with combination metformin and sulfonylurea. Tayek JA Diabetes Metab Res Rev; 2007 Feb; 23(2):85-6. PubMed ID: 17262894 [No Abstract] [Full Text] [Related]
14. Sulfonylurea use is associated with larger infarct size in patients with diabetes and ST-elevation myocardial infarction. Abdelmoneim AS; Welsh RC; Eurich DT; Simpson SH Int J Cardiol; 2016 Jan; 202():126-30. PubMed ID: 26386939 [TBL] [Abstract][Full Text] [Related]
15. Newer Sulfonylureas Not Associated with Increased Mortality, MIs, or Strokes. Barry HC Am Fam Physician; 2016 Sep; 94(5):386. PubMed ID: 27583428 [No Abstract] [Full Text] [Related]
16. Glimepiride-induced vasculitis: a case report. Ben Salem C; Hmouda H; Bouraoui K Br J Clin Pharmacol; 2007 Jul; 64(1):113-4. PubMed ID: 17324240 [No Abstract] [Full Text] [Related]
17. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Meier JJ; Gallwitz B; Schmidt WE; Mügge A; Nauck MA Heart; 2004 Jan; 90(1):9-12. PubMed ID: 14676228 [TBL] [Abstract][Full Text] [Related]
18. Managing the diabetic patient with acute myocardial infarction. Fisken RA Diabet Med; 1998 Nov; 15(11):980. PubMed ID: 9827854 [No Abstract] [Full Text] [Related]
19. Risk of a first-ever acute myocardial infarction and all-cause mortality with sulphonylurea treatment: A population-based cohort study. van Dalem J; Brouwers MCGJ; Stehouwer CDA; Krings A; Klungel OH; Driessen JHM; de Vries F; Burden AM Diabetes Obes Metab; 2018 Apr; 20(4):1056-1060. PubMed ID: 29171906 [TBL] [Abstract][Full Text] [Related]
20. A comment on 'the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy'. Chang Y; Choi NK; Hahn S; Park BJ Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1072-3; author reply 1073-4. PubMed ID: 17907252 [No Abstract] [Full Text] [Related] [Next] [New Search]